All In Biotech

Drug Trial Radar · NCT07829549

Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

A Randomized, Double-blind, Multicenter Phase III Study of RC148 Combined With Platinum-Based Chemotherapy Versus Tislelizumab Combined With Platinum-Based Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Oct 10, 2026

Primary completion

Apr 2031

Study completion Aug 2031

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of RC148 plus platinum-based chemotherapy versus tislelizumab plus platinum-based chemotherapy in trial participants with previously untreated locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV), non-squamous non-small cell lung cancer without actionable genomic alterations.

Conditions

  • Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations

Interventions

  • RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin InjectionDrug

    RC148, Pemetrexed Disodium, Carboplatin

  • Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin InjectionDrug

    Tislelizumab, Pemetrexed Disodium, Carboplatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival assessed by BIRC per RECIST v1.1Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lin Wu

    Hunan, Changsha, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.